Table 4.
Clinical outcomes according to PNI trajectory category.
| Outcome | Stable/improving (n = 219) | Mild decline (n = 251) | Marked decline (n = 210) | p-value |
|---|---|---|---|---|
| Baseline PNI | 48.9 ± 5.6 | 46.8 ± 5.7 | 44.1 ± 6.3 | <0.001 |
| End-treatment PNI | 48.2 ± 5.9 | 42.9 ± 5.8 | 36.8 ± 6.1 | <0.001 |
| Mean weight change, % | −2.7 ± 3.5 | −5.1 ± 4.2 | −8.2 ± 5.1 | <0.001 |
| Clinically significant weight loss | 45 (20.5) | 117 (46.6) | 141 (67.1) | <0.001 |
| Hypoalbuminemia at treatment completion | 54 (24.7) | 121 (48.2) | 138 (65.7) | <0.001 |
| Severe treatment-related toxicity | 28 (12.8) | 65 (25.9) | 85 (40.5) | <0.001 |
| Severe oral mucositis* | 14 (14.6) | 32 (27.8) | 47 (48.5) | <0.001 |
| Treatment interruption | 17 (7.8) | 42 (16.7) | 56 (26.7) | <0.001 |
| Hospitalization | 13 (5.9) | 29 (11.6) | 47 (22.4) | <0.001 |
| Radiotherapy non-completion | 5 (2.3) | 12 (4.8) | 22 (10.5) | 0.002 |
*Severe oral mucositis was assessed among patients with head and neck malignancies.